Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11560689 | 0.87 | ALOX5 (0.49) | ALOX5PTGS2ELANE | |
| SCHEMBL8475524 | 0.85 | HMGCR (0.43) | HMGCRGABRA1GABRB2ALOX5TAAR1 | |
| SCHEMBL457842 | 0.84 | TAAR1 (0.37) | TAAR1PTGS2ALDH1A1 | |
| SCHEMBL7388700 | 0.83 | TAAR1 (0.35) | TAAR1ADRA1ASMN1; SMN2SIGMAR1 | |
| SCHEMBL27588198 | 0.83 | TAAR1 (0.35) | TAAR1ADRA1AGAAALDH1A1SIGMAR1 | |
| SCHEMBL4601776 | 0.83 | TAAR1 (0.35) | TAAR1ADRA1AGAAALDH1A1SIGMAR1 | |
| SCHEMBL21268391 | 0.80 | CYP1A2 (0.40) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6313680 | 0.80 | HTR2A (0.46) | — | |
| SCHEMBL3360209 | 0.80 | TAAR1 (0.33) | ALOX5TAAR1PTGS2ADRA1ASMN1; SMN2 | |
| SCHEMBL2439647 | 0.79 | CTSS (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | claimed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | claimed |
| EP-4065566-A1 | TRPM8 MODULATORS | Givaudan SA (CH) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105261-A1 | TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-0649420-B1 | PROCESS FOR THE PREPARATION OF 3,3-DIARYL ACRYLIC ACID AMIDES | SHELL INT RESEARCH (NL) | 1997-05-02 | — | — | EP | disclosed |
| EP-0726257-A1 | 1-(Hetero)Arylvinyl-5H-2,3-benzodiazepine derivatives useful for the treatment of central nervous system disorders, and benzopyrylium intermediates for their preparation | EGIS GYOGYSZERGYAR RT. (HU) | 1996-08-14 | — | — | EP | disclosed |
| US-5495019-A | Process for the preparation of 3,3-diaryl acrylic acid amides | AMERICAN CYANAMID COMPANY (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0649420-A1 | NEW PROCESS FOR THE PREPARATION OF 3,3-DIARYL ACRYLIC ACID AMIDES. | SHELL INT RESEARCH (NL) | 1995-04-26 | — | — | EP | disclosed |
| EP-0294907-B1 | Process for the preparation of 3,3-diaryl acrylic acid amides | SHELL INT RESEARCH (NL) | 1994-06-01 | — | — | EP | disclosed |
| WO-1994001424-A1 | NEW PROCESS FOR THE PREPARATION OF 3,3-DIARYL ACRYLIC ACID AMIDES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1994-01-20 | — | — | WO | disclosed |
| US-4933449-A | Preparing 3-(4 chlorophenyl)-3-(3,4-dimethoxyphenyl) acrylic acid morpholide in the presence of potassium tert-butylate | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1990-06-12 | — | — | US | disclosed |
| EP-0294907-A1 | Process for the preparation of 3,3-diaryl acrylic acid amides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-12-14 | — | — | EP | disclosed |
| US-4173630-A | N2 Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | HMGCR 2117/4885GABRA1 3960/4885GABRB2 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.